Chapter 4: Relative contributions of adiposity in childhood and adulthood to vascular health in young adults.
Chapter 5: Resting heart rate and the association of physical fitness with carotid artery stiffness.
Chapter 6: Vigorous physical activity and carotid distensibility in young and mid-aged adults.
Chapter 7: The association of sitting time with carotid artery stiffness in young adults.
Chapter 8: Summary, implications, future directions and conclusions
Concluding remarks
This chapter provides an overview of CVD burden and risk factors. The evidence from studies reviewed in the preceding text of this chapter points out that (1) the development of CVD is a long process and has origins from early stages of life, (2) long-term prevention of CVD may contribute to reduce CVD burden, and (3) improving lifestyle risk factors including fatness, fitness, physical activity and sedentary behaviour may reduce CVD risk, but their
relationships with early stages of CVD are less clear and need to be examined among younger adults. This research aims to examine the relationships of these lifestyle risk factors with early stages of CVD assessed by subclinical markers of vascular health among younger adults to help to fill the current evidence gaps. The novel findings produced by this research may advance our knowledge in the field.
Postscript
The next chapter will describe the participants and methods of the four population-based samples used in this thesis.
References
1. The Global Burden of Disease: 2004 update. Geneva: World Health Organization; 2008.
2. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization 2011.
3. The top 10 causes of death in 2011 (Fact sheet N°310). Geneva: World Health Organization 2013.
4. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability- adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a
systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-223.
5. World Health Statistics 2012. Geneva: World Health Organization; 2012.
6. Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. Millbank Memorial Fund Q. 1971;49:509-38.
7. Olshansky SJ, Ault AB. The fourth stage of the epidemiologic transition: the age of delayed degenerative diseases. Milbank Q. 1986;64(3):355-91.
8. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of
urbanization. Circulation. 2001;104(22):2746-53.
9. Causes of death 2011: Australian Bureau of Statistics. March 2013.
10. The burden of cardiovascular disease in Australia for the year 2003: National Heart Foundation of Australia (Report by Vos T and Begg S, Centre for Burden of Disease and Cost-effectiveness, University of Queensland School of Population Health).2007.
11. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998;97(6):596-601.
12. Viet Nam Burden of Disease and Injury Study 2008. Hanoi: Hanoi School of Public Health.2011.
13. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure:
prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765-74.
14. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, Ga: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2004.
15. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12- yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.
Diabetes Care. 1993;16(2):434-44.
16. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long-term coronary heart disease mortality in different
cultures. Twenty-five-year follow-up of the seven countries study. JAMA. 1995;274(2):131-6. 17. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet.
1990;335(8693):827-38.
18. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta- analysis. BMJ. 2003;326(7404):1423.
19. Grundy SM, Pasternak R, Greenland P, Smith S, Jr., Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100(13):1481-92.
20. Rosenman RH, Friedman M. Neurogenic factors in pathogenesis of coronary heart disease. Med Clin North Am. 1974;58(2):269-79.
21. Braunwald E. Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337(19):1360-9.
22. Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation. 1998;97(11):1095-102.
23. Futterman LG, Lemberg L. Fifty percent of patients with coronary artery disease do not have any of the conventional risk factors. Am J Crit Care. 1998;7(3):240-4.
24. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7):898-904. 25. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290(7):891-7.
26. Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women.
JAMA. 1999;282(21):2012-8.
27. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of
potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52.
28. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al.
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-72. 29. Mendis S, Puska P, Norrving B, editors. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization (in collaboration with the World Heart Federation and World Stroke Organization); 2011.
30. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287(8):1003-10.
31. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358(9294):1682-6.
32. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291-7.
33. Franklin SS, Gustin Wt, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96(1):308-15.
34. Benetos A, Zureik M, Morcet J, Thomas F, Bean K, Safar M, Ducimetiere P, Guize L. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is
associated with a higher cardiovascular mortality in men. J Am Coll Cardiol. 2000;35(3):673- 80.
35. Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med. 2000;160(8):1085-9.
36. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al.
Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588-605.
37. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13.
38. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356(9246):1955-64.
39. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009;(3):CD001841.
40. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev. 2009;(4):CD000028.
41. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
42. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, et al.
Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23(1):7-17.
43. Blann AD, Kirkpatrick U, Devine C, Naser S, McCollum CN. The influence of acute smoking on leucocytes, platelets and the endothelium. Atherosclerosis. 1998;141(1):133-9. 44. Campisi R, Czernin J, Schoder H, Sayre JW, Schelbert HR. L-Arginine normalizes coronary vasomotion in long-term smokers. Circulation. 1999;99(4):491-7.
45. Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, Webb DJ. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a
mechanism for arterial thrombosis and myocardial infarction. Circulation. 1999;99(11):1411- 5.
46. Spagnoli LG, Mauriello A, Palmieri G, Santeusanio G, Amante A, Taurino M. Relationships between risk factors and morphological patterns of human carotid atherosclerotic plaques. A multivariate discriminant analysis. Atherosclerosis. 1994;108(1):39-60.
47. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997;336(18):1276-82.
48. Friedman GD, Siegelaub AB, Seltzer CC, Feldman R, Collen MF. Smoking habits and the leukocyte count. Arch Environ Health. 1973;26(3):137-43.
49. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.
Circulation. 2000;101(15):1767-72.
50. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ. 1989;298(6676):784-8. 51. Benowitz NL. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. N Engl J Med. 1988;319(20):1318-30.
52. Quillen JE, Rossen JD, Oskarsson HJ, Minor RL, Jr., Lopez AG, Winniford MD. Acute effect of cigarette smoking on the coronary circulation: constriction of epicardial and resistance vessels. J Am Coll Cardiol. 1993;22(3):642-7.
53. Rampling MW. Clotting factors and rheology: mechanisms of damage and
intervention. In: Poulter N, Sever P, Thom S, editors. Cardiovascular Disease: Risk Factors and Intervention. Oxford: Radcliffe Medical Press; 1993. p. 201–13.
54. Narkiewicz K, van de Borne PJ, Hausberg M, Cooley RL, Winniford MD, Davison DE, Somers VK. Cigarette smoking increases sympathetic outflow in humans. Circulation. 1998;98(6):528-34.
55. Keil U, Liese AD, Hense HW, Filipiak B, Doring A, Stieber J, Lowel H. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984- 1992. Monitoring Trends and Determinants in Cardiovascular Diseases. Eur Heart J. 1998;19(8):1197-207.
56. Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med. 1987;317(21):1303-9.
57. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000;343(1):16-22. 58. Rosenberg L, Kaufman DW, Helmrich SP, Miller DR, Stolley PD, Shapiro S.
Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA. 1985;253(20):2965-9.
59. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ. 1989;298(6667):165-8.
60. U.S. Dept of Health and Human Services. The Health Benefits of Smoking Cessation. A Report of the Surgeon General.: USDHHS, Centers for Disease Control. Office of Smoking and Health. 1990. DHHS Publication (CDC) 90-8416. .
61. Sparrow D, Dawber TR. The influence of cigarette smoking on prognosis after a first myocardial infarction. A report from the Framingham study. J Chronic Dis. 1978;31(6- 7):425-32.
62. Salonen JT. Stopping smoking and long-term mortality after acute myocardial infarction. Br Heart J. 1980;43(4):463-9.
63. Diabetes Atlas, Third Edition. Brussels: International Diabetes Federation. 2006.
64. Dunstan D, Zimmet P, Welborn T, Sicree R, Armstrong T, Atkins R, et al. Diabesity & Associated Disorders in Australia - 2000. The Accelerating Epidemic. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Melbourne. 2001.
65. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: a report of a WHO/IDF consultation. Geneva: World Health Organization. 2006.
66. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. Coronary artery disease in IDDM. Gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol. 1996;16(6):720-6.
67. Wilson PW. Diabetes mellitus and coronary heart disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S89-100.
68. Geiss LS, Herman WH, Smith PJ. Chapter 11: Mortality in Non-Insulin-Dependent Diabetes. Diabetes in America, 2nd Edition. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995. p. 233–57.
69. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-34.
70. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100(10):1134-46.
71. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol. 1989;14(1):49-57. 72. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
73. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol. 1992;2(1-2):23-8.
74. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256(20):2823-8.
75. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351-64.
76. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.
JAMA. 1984;251(3):365-74.
77. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis.
Science. 1986;232(4746):34-47.
78. Gordon DJ. Cholesterol lowering reduces mortality: the statins. In: Grundy SM, editor. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc.; 2000. p. 299-311.
79. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al.
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410-8.
80. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, et al.
Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000;102(16):1893-900. 81. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ.
1994;308(6925):367-72.
82. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549-55. 83. Australian Health Survey: First Results, 2011-12 (cat. no. 4364.0.55.001): Australian Bureau of Statistics. 2012.
84. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med. 1995;333(11):677-85.
85. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867-72.
86. Van Itallie TB. Health implications of overweight and obesity in the United States.
Ann Intern Med. 1985;103(6 ( Pt 2)):983-8.
87. Alpert MA, Hashimi MW. Obesity and the heart. Am J Med Sci. 1993;306(2):117-23. 88. Duflou J, Virmani R, Rabin I, Burke A, Farb A, Smialek J. Sudden death as a result of heart disease in morbid obesity. Am Heart J. 1995;130(2):306-13.
89. Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba Study. Am J Cardiol. 1977;39(3):452-8.
90. Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997;96(9):3248-50.
91. Lloyd-Jones DM, Liu K, Colangelo LA, Yan LL, Klein L, Loria CM, Lewis CE, Savage P. Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. Circulation. 2007;115(8):1004-11.
92. Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol. 2007;50(22):2128-32.
93. O'Flaherty M, Ford E, Allender S, Scarborough P, Capewell S. Coronary heart disease trends in England and Wales from 1984 to 2004: concealed levelling of mortality rates among young adults. Heart. 2008;94(2):178-81.
94. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factors. Med J Aust. 2000;172(12):592-6.
95. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238-45.
96. Fletcher GF, Balady G, Blair SN, Blumenthal J, Caspersen C, Chaitman B, et al.
Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association.
Circulation. 1996;94(4):857-62.
97. Gordon NF, Gulanick M, Costa F, Fletcher G, Franklin BA, Roth EJ, Shephard T. Physical activity and exercise recommendations for stroke survivors: an American Heart Association scientific statement from the Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention; the Council on Cardiovascular Nursing; the Council on Nutrition, Physical Activity, and Metabolism; and the Stroke Council. Stroke. 2004;35(5):1230-40.
98. Leon AS, Franklin BA, Costa F, Balady GJ, Berra KA, Stewart KJ, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2005;111(3):369-76.
99. Powell KE, Thompson PD, Caspersen CJ, Kendrick JS. Physical activity and the incidence of coronary heart disease. Annu Rev Public Health. 1987;8:253-87.
100. Morris JN, Clayton DG, Everitt MG, Semmence AM, Burgess EH. Exercise in leisure time: coronary attack and death rates. Br Heart J. 1990;63(6):325-34.
101. Nocon M, Hiemann T, Muller-Riemenschneider F, Thalau F, Roll S, Willich SN. Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil. 2008;15(3):239-46.
102. Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, Thompson DR,